Rule 3.19A.2

# Appendix 3Y

# Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Emefcy Group Limited (ASX: EMC)
ABN	52 127 734 196

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Eytan Levy
Date of last notice	29 December 2015

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Beneficial owner of ordinary shares held in the name of ESOP Management and Trust Services Ltd.	
Date of change	12 April 2016	
No. of securities held prior to change	6,409,416 ordinary shares held in the name of ESOP Management and Trust Services Ltd. 1,000,000 options with exercise price of \$0.30, expiring 18/12/18 1,000,000 options with exercise price of \$0.40, expiring 18/12/2019	
Class	Ordinary shares held in the name of ESOP Management and Trust Services Ltd. (escrowed until 23 December 2017)	
Number acquired	2,858,394	
Number disposed	Not applicable	

<sup>+</sup> See chapter 19 for defined terms.

Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Part of the deferred consideration for the Company's acquisition of Emefcy Limited, Israel.
No. of securities held after change	9,267,810 ordinary shares held in the name of ESOP Management and Trust Services Ltd. 1,000,000 options with exercise price of \$0.30, expiring 18/12/18 1,000,000 options with exercise price of \$0.40, expiring 18/12/2019
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Ordinary shares issued as part consideration, upon satisfaction of the first commercial milestone under the Share Purchase Agreement. The issue of this deferred consideration was approved by the Company's shareholders at a general meeting on 17 November 2015.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Share Purchase Agreement, the terms of which were	
	summarised in section 13.1(a) of the Company's	
	Replacement Prospectus dated 23 October 2015.	
Nature of interest	In accordance with the terms of the Share Purchase	
	Agreement, a right to receive shares in the Company as	
	deferred consideration for the acquisition of Emefcy	
	Limited, Israel.	
Name of registered holder	Not applicable	
(if issued securities)		
,		
Date of change	12 April 2016	
-	-	
No. and class of securities to which	Up to a total of 5,962,945 ordinary shares following	
interest related prior to change	satisfaction of prescribed milestones (summarised in	
Note: Details are only required for a contract in relation	section 13.6 of the Company's Replacement Prospectus	
to which the interest has changed	dated 23 October 2015).	
Interest acquired	Not applicable	
·		
Interest disposed	2,858,394 ordinary shares were issued as a result of the	
Interest dispessed	satisfaction of the first milestone.	
Value/Consideration		
Note: If consideration is non-cash, provide details and an	Part of the deferred consideration for the Company's	
estimated valuation	acquisition of Emefcy Limited, Israel.	
Interest after change	Up to a total of 2.104.551 andinomy above fallering	
Interest after change	Up to a total of 3,104,551 ordinary shares following	
	satisfaction of prescribed milestones (summarised in	
	section 13.6 of the Company's Replacement Prospectus	
	dated 23 October 2015).	

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

## Part 3 – +Closed period

Were the interests in the securities or contracts detailed above	No
traded during a +closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

<sup>+</sup> See chapter 19 for defined terms.